다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Transplant immunology, v.5 no.4, 1997년, pp.299 - 302
Bennett, C Frank (Address for correspondence: CF Bennett, Isis Pharmaceuticals Inc., 2280 Faraday Ave, Carlsbad, CA 92009, USA.) , Stepkowski, Stanislaw M (Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School at Houston, Houston, Texas U.S.A.)
초록이 없습니다.
J Heart Lung Transplant Hosenpud 11 9 1992 Cardiac allograft vasculopathy: current concepts, recent developments, and future directions
Transplantation Paul 53 1169 1992 10.1097/00007890-199206000-00001 Chronic vascular rejection of the heart and the kidney - have rational treatment options emerged?
Clin Transplantation Orosz 10 100 1996 Local cellular immunology of experimental transplant vascular sclerosis
Science Ohno 265 781 1994 10.1126/science.8047883 Gene therapy for vascular smooth muscle cell proliferation after arterial injury
Science Lau 273 109 1996 10.1126/science.273.5271.109 Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice
Ann Rev Biochem Green 55 569 1986 10.1146/annurev.bi.55.070186.003033 The Role of Antisense RNA in Gene Regulation
Sci. Am Weintraub 262 40 1990 10.1038/scientificamerican0190-40 Antisense RNA and DNA
Proc Nat Acad Sci USA Iyer 93 9960 1996 10.1073/pnas.93.18.9960 Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense
Sci Am Cech 255 64 1986 10.1038/scientificamerican1186-64 RNA as an enzyme
Science Stein 261 1004 1993 10.1126/science.8351515 Antisense oligonucleotides as therapeutic agents - is the bullet really magical?
Ann Rev Pharmacol Toxicol Crooke 36 107 1996 10.1146/annurev.pa.36.040196.000543 Progress in antisense oligonucleotide therapeutics
Curr Opin Struct Biol Cech 2 605 1992 10.1016/0959-440X(92)90093-M Ribozyme engineering
J Mol Biol Sioud 224 831 1992 10.1016/0022-2836(92)90244-E Performed ribozyme destroys tumour necrosis factor mRNA in human cells
Curr Opin Struct Biol Sun 3 345 1993 10.1016/S0959-440X(05)80105-8 Oligonucleotide-directed triple-helix formation
Science Bielinska 250 997 1990 10.1126/science.2237444 Regulation of gene expression with double-stranded phosphorothioate oligonucleotides
J Immunol Stepkowski 153 5336 1994 10.4049/jimmunol.153.11.5336 Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities
Proc Nat Acad Sci USA Morishita 90 8474 1993 10.1073/pnas.90.18.8474 Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia
Proc Nat Acad Sci USA Mann 92 4502 1995 10.1073/pnas.92.10.4502 Genetic engineering of vein grafts resistant to atherosclerosis
Proc Nat Acad Sci USA Morishita 92 5855 1995 10.1073/pnas.92.13.5855 A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
J Clin Invest Mann 99 1295 1997 10.1172/JCI119288 Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts
J Immunol Bennett 152 3530 1994 10.4049/jimmunol.152.7.3530 Inhibition of endothelial cell-leucocyte adhesion molecule expression with antisense oligonucleotides
Adv Pharmacol Bennett 28 1 1994 10.1016/S1054-3589(08)60492-5 Regulation of endothelial cell adhesion molecule expression with antisense oligonucleotides
Ann Rev Pharmacol Toxicol Crooke 32 329 1992 10.1146/annurev.pa.32.040192.001553 Therapeutic applications of oligonucleotides
Nature Wagner 372 333 1994 10.1038/372333a0 Gene inhibition using antisense oligodeoxynucleotides
Crooke 1995
TIBTECH Stein 14 147 1996 10.1016/0167-7799(96)20006-X Phosphorothioate antisense oligodeoxynucleotides: questions of specificity
J Biol Chem Chiang 266 18162 1991 10.1016/S0021-9258(18)55250-9 Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
Exp Cell Res Miele 214 231 1994 10.1006/excr.1994.1253 Enhanced metastatic ability of TNF-α-treated malignant melanoma cells is reduced by initercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides
J Invest Dermatol Nestle 103 569 1994 10.1111/1523-1747.ep12396876 Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes
J Clin Invest Yan 91 986 1993 10.1172/JCI116320 Human/severe combined immunodeficient mouse chimeras: an experimental in vivo model system to study the regulation of human endothelial cell-leucocyte adhesion molecules
Proc Nat Acad Sci USA Murray 91 9146 1994 10.1073/pnas.91.19.9146 Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse
Am J Pathol Christofidou-Solomidou 150 631 1997 Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras
Science Isobe 255 1125 1992 10.1126/science.1347662 Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
Transplant Proc Katz 27 3214 1995 Efficacy of ICAM-1 antisense oligonucleotide in pancreatic islet transplantation
J Clin Invest Kumasaka 97 2362 1996 10.1172/JCI118679 The role of the Intercellular Adhesion Molecule-1 (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice
J Pharmacol Exp Ther Bennett 280 988 1997 An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
Kidney Int Haller 50 473 1996 10.1038/ki.1996.338 Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat
Toxicol Henry 120 1450 1997 10.1016/S0300-483X(97)03661-5 Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide: 2) 4-week study in cynomolgus monkeys
Antisense Nuc Drug Dev Henry 7 473 1997 10.1089/oli.1.1997.7.473 Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide, following repeated intravenous administration: 1) 4-week study in CD-1 mice
Proc Nat Acad Sci USA Sligh 90 8529 1993 10.1073/pnas.90.18.8529 Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1
J Exp Med Xu 180 95 1994 10.1084/jem.180.1.95 Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice
Levin 1997 Toxicity of oligodeoxynucleotide therapeutic agents
Anti-Cancer Drug Design Monteith 1997 Immune stimulation-A class effect of phosphorothioate oligonucleotides in rodents
J Pharmacol Exp Therap Glover 252 1173 1997 Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302)
Gastroenterology Yacyshyn 112 A1123 1997 Efficacy and safety of ISIS 2302 (ICAM-1 antisense oligonucleotide) treatment of steroid-dependent Crohn's disease
Biochem Pharmacol Zhao 51 173 1995 10.1016/0006-2952(95)02177-9 Effect of different chemically modified oligodeoxynucleotides on immune stimulation
J Pharmacol Exp Therap Crooke 277 923 1996 Pharmacokinetic properties of several novel oligonucleotide analogs in mice
J Pharmacol Exp Ther Zhang 278 971 1996 Pharmacokinetics and tissue distribution of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration
J Biol Chem Baker 272 11994 1997 10.1074/jbc.272.18.11994 2′-O-(2-methoxy)ethyl modified anti-ICAM-1 oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in HUVECs
Antisense Nuc Acid Drugs Dev Boggs 7 461 1997 10.1089/oli.1.1997.7.461 Characterization and modulation of immune stimulation by modified oligonucleotides
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.